Skip to main content

Table 1 Baseline characteristics and protein levels at baseline and 7 days after treatment with prednisolone or infliximab. Data are mean ± SD or median (25th percentile; 75th percentile)

From: The IGF system in patients with inflammatory bowel disease treated with prednisolone or infliximab: potential role of the stanniocalcin-2 / PAPP-A / IGFBP-4 axis

Characteristics

Healthy subjects

Prednisolone (n = 17)

Infliximab (n = 21)

 
  

Day 0

Day 7

Day 0

Day 7

P Group, day 0

Ulcerative colitis/ Crohn’s disease (n)

 

13/4

 

7/14

 

0.008

Age (years)

 

34.4 ± 8.9

 

30.5 ± 11.0

 

0.243

Male/female (n)

 

10/7

 

10/11

 

0.492

BMI (kg/m2)

 

23.3 ± 4.5

 

25.1 ± 5.8

 

0.306

SCCAI

 

9 (7;10)

2 (1;2)**

8 (5;9)

2 (1;4)*

0.537

HBI

 

8 (5;13)

4 (1;6)*

5.5 (3;8)

2 (1;3)**

0.243

eGFR

 

98 (70;104)

94 (89;101)

102 (94;122)

101 (93;114)

0.008

CRP (mg/L)

 

12.8 (3.6;21.5)

7.2 (3.5;21.2)**

7.2 (3.5;21.2)

2.7 (1.4;7.9)*

0.587

ESR (mm/h)

 

14 (7;27)

6 (5;10)**

13.5 (8.5;19.5)

11 (7;16)*

0.647

Orosomucoid (g/L)

 

1.4 ± 0.4

1.2 ± 0.5*

1.3 ± 0.4

1.0 ± 0.3**

0.383

Calprotectin (mg/kg)

 

2072 ± 1254

1100 ± 1124**

1569 ± 1099

810 ± 777**

0.311

Cortisol (μg/L)

 

129 (107;255)

435 (27;941)

125 (104;154)

129 (110;141)

0.364

Insulin (pmol/L)

 

44 ± 38

42 ± 17

45 ± 25

49 ± 26

0.865

TNF-α (ng/L)

 

1.5 ± 1.0

1.1 ± 1.9

1.1 ± 0.9

11.5 ± 6.0**

0.173

IL-6 (ng/L)

 

2.9 ± 2.6

1.6 ± 1.5*

2.8 ± 1.6

1.7 ± 1.7*

0.973

IGF-I (μg/L)

 

128 ± 36

185 ± 67**

159 ± 33

178 ± 50*

0.009

IGF-II (μg/L)

 

502 ± 61

502 ± 60

495 ± 71

518 ± 75*

0.746

IGF bioactivity (μg/L)

 

1.08 ± 0.36

1.34 ± 0.52*

1.23 ± 0.42

1.33 ± 0.45

0.260

IGFBP-3 (μg/L)

 

4120 ± 583

4332 ± 771

4220 ± 687

4417 ± 687*

0.638

IGFBP-4 (μg/L)

174 ± 79

184 (146;315)

132 (111;188)*

183 (152;207)

164 (97;209)*

0.410

CT-IGFBP-4 (μg/L)

72 ± 18

112 ± 33†

79 ± 41**

99 ± 35†

78 ± 35**

0.246

CT-IGFBP-4/IGFBP-4 ratio

0.41 (0.29;0.53)

0.61 ± 0.27†

0.57 ± 0.35†

0.55 ± 0.15†

0.59 ± 0.36†

0.443

NT-IGFBP-4 (μg/L)

153 ± 41

257 ± 111†

179 ± 93**

207 ± 76†

170 ± 78**

0.108

NT-IGFBP-4/IGFBP-4 ratio

0.80 (0.61;0.99)

1.34 ± 0.57†

1.28 ± 0.72†

1.16 ± 0.31†

1.30 ± 0.84†

0.223

PAPP-A (μg/L)

0.81 ± 0.26

1.17 ± 0.66†

1.21 ± 0.56†

0.76 ± 0.37

0.87 ± 0.33*

0.019

STC2 (μg/L)

25.0 (21.2;28.1)

22.2 ± 5.2

21.5 ± 4.8

22.9 ± 5.6

24.3 ± 7.6

0.698

  1. Categorical variables are indicated as numbers (n) of patients. Comparison of groups on day 0 was performed by Student’s t-test, and comparison of observations on day 0 and day 7 within the same treatment group were performed using paired t-test. CRP, ESR, and cortisol were analyzed using the nonparametric Wilcoxon matched-pairs signed-ranks test or the Mann–Whitney U-statistics as appropriate. Differences in protein concentrations between patients and controls were assessed by unpaired t-test. Categorical variables were compared using χ2-test. *P < 0.05, **P < 0.005 when compared to day 0 within the same treatment group. †p < 0.05 for differences between IBD patients and controls on day 0 or day 7
  2. BMI body mass index, CRP C-reactive protein, CT C-terminal, eGFR estimated glomerular filtration rate, ESR erythrocyte sedimentation rate, HBI Harvey–Bradshaw Index, IGF insulin-like growth factor, IGFBP IGF binding protein, IL-6 interleukin-6, NT N-terminal, PAPP-A pregnancy-associated plasma protein-A, SCCAI Simple Clinical Colitis Activity Index, STC2 Stanniocalcin-2, TNF-α tumour necrosis factor-α